Scilex Holding Co SEC filings SCLXW
Scilex Holding Co has 742 filings in SEC EDGAR's recent list, going back to Aug 19, 2020. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 11, 2026 | — |
| CORRESP | Letter to the SEC | Jun 9, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2026 | — |
| EFFECT | Filing | May 22, 2026 | — |
| CORRESP | Letter to the SEC | May 20, 2026 | — |
| NT 10-Q | Filing | May 15, 2026 | Mar 31, 2026 |
| CORRESP | Letter to the SEC | Apr 30, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 24, 2026 | — |
| NT 10-K | Filing | Apr 1, 2026 | Dec 31, 2025 |
| UPLOAD | Letter from the SEC | Feb 20, 2026 | — |
| DRS | Filing | Feb 13, 2026 | — |
| RW | Filing | Jan 6, 2026 | — |
| EFFECT | Filing | Dec 29, 2025 | — |
| CORRESP | Letter to the SEC | Dec 23, 2025 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2025 | — |
| D | Filing | Oct 14, 2025 | — |
| CORRESP | Letter to the SEC | Aug 29, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2025 | — |
| EFFECT | Filing | May 13, 2025 | — |
| EFFECT | Filing | May 13, 2025 | — |
| EFFECT | Filing | May 13, 2025 | — |
| PRER14A | Filing | Feb 26, 2025 | — |
| NT 10-Q | Filing | Nov 14, 2024 | Sep 30, 2024 |
| 425 | Filing | Nov 6, 2024 | — |
| 425 | Filing | Sep 3, 2024 | — |
| EFFECT | Filing | Jul 25, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 23, 2024 | — |
| CORRESP | Letter to the SEC | Jul 23, 2024 | — |
| EFFECT | Filing | Mar 29, 2024 | — |
| EFFECT | Filing | Mar 29, 2024 | — |
| EFFECT | Filing | Mar 29, 2024 | — |
| EFFECT | Filing | Mar 29, 2024 | — |
| EFFECT | Filing | Mar 8, 2024 | — |
| EFFECT | Filing | Jan 11, 2024 | — |
| CORRESP | Letter to the SEC | Jan 9, 2024 | — |
| CORRESP | Letter to the SEC | Jan 8, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 5, 2024 | — |
| EFFECT | Filing | Nov 22, 2023 | — |
| CORRESP | Letter to the SEC | Nov 20, 2023 | — |
| CORRESP | Letter to the SEC | Nov 6, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2023 | — |
| D | Filing | Oct 5, 2023 | — |
| RW | Filing | Sep 27, 2023 | — |
| EFFECT | Filing | Apr 19, 2023 | — |
| CORRESP | Letter to the SEC | Apr 17, 2023 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2023 | — |
| EFFECT | Filing | Mar 20, 2023 | — |
| EFFECT | Filing | Mar 17, 2023 | — |
| EFFECT | Filing | Mar 17, 2023 | — |
| EFFECT | Filing | Jan 20, 2023 | — |
| CORRESP | Letter to the SEC | Jan 18, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 18, 2023 | — |
| EFFECT | Filing | Dec 27, 2022 | — |
| CORRESP | Letter to the SEC | Dec 22, 2022 | — |
| CORRESP | Letter to the SEC | Dec 19, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2022 | — |
| EFFECT | Filing | Dec 9, 2022 | — |
| CORRESP | Letter to the SEC | Dec 7, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 6, 2022 | — |
| 25-NSE | Delisting notice | Nov 10, 2022 | — |
| SEC STAFF LETTER | Filing | Oct 31, 2022 | — |
| 425 | Filing | Oct 31, 2022 | — |
| EFFECT | Filing | Oct 28, 2022 | — |
| CORRESP | Letter to the SEC | Oct 26, 2022 | — |
| CORRESP | Letter to the SEC | Oct 26, 2022 | — |
| CORRESP | Letter to the SEC | Oct 24, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 21, 2022 | — |
| 425 | Filing | Oct 18, 2022 | — |
| CORRESP | Letter to the SEC | Oct 18, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2022 | — |
| CORRESP | Letter to the SEC | Oct 4, 2022 | — |
| UPLOAD | Letter from the SEC | Sep 23, 2022 | — |
| 425 | Filing | Sep 14, 2022 | — |
| CORRESP | Letter to the SEC | Sep 13, 2022 | — |
| 425 | Form 425 | Aug 31, 2022 | — |
| 425 | Form 425 | Aug 16, 2022 | — |
| CORRESP | Letter to the SEC | Aug 10, 2022 | — |
| SEC STAFF LETTER | Filing | Aug 3, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2022 | — |
| CORRESP | Letter to the SEC | Jul 20, 2022 | — |
| SEC STAFF LETTER | Filing | Jul 15, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 11, 2022 | — |
| 425 | Form 425 | Jul 7, 2022 | — |
| 425 | Form 425 | Jul 5, 2022 | — |
| 425 | Current report | Jul 5, 2022 | — |
| CORRESP | Letter to the SEC | Jun 24, 2022 | — |
| 425 | Form 425 | Jun 16, 2022 | — |
| UPLOAD | Letter from the SEC | Jun 9, 2022 | — |
| 425 | Filing | Jun 3, 2022 | — |
| 425 | Filing | Jun 3, 2022 | — |
| 425 | Current report | May 23, 2022 | — |
| 425 | Form 425 | May 19, 2022 | — |
| 425 | Form 425 | May 16, 2022 | — |
| 425 | Form 425 | May 11, 2022 | — |
| 425 | Form 425 | Apr 29, 2022 | — |
| 425 | Filing | Apr 26, 2022 | — |
| 425 | Form 425 | Apr 25, 2022 | — |
| 425 | Form 425 | Apr 13, 2022 | — |
| 425 | Form 425 | Apr 4, 2022 | — |
| 425 | Form 425 | Apr 4, 2022 | — |
| 425 | Current report | Mar 21, 2022 | — |
| 425 | Form 425 | Mar 18, 2022 | — |
| 425 | Current report | Feb 18, 2022 | — |
| NT 10-Q | Filing | Aug 16, 2021 | Jun 30, 2021 |
| NT 10-Q | Notification of late filing | May 17, 2021 | Mar 31, 2021 |
| EFFECT | Filing | Jan 6, 2021 | — |
| CERT | Filing | Jan 6, 2021 | — |
| 8-A12B | Registration of certain classes of securities | Jan 6, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| CORRESP | Letter to the SEC | Dec 28, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 17, 2020 | — |
| DRS | Filing | Aug 19, 2020 | — |
Showing 113 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SCLX (Nasdaq), SCLXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Palo Alto, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1820190
- Former names
- Scilex Holding Company/DE (until Nov 30, 2022); Vickers Vantage Corp. I (until Nov 15, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.